Chemomab Therapeutics Ltd Stock Price, News & Analysis

Chemomab Therapeutics (Nasdaq: CMMB) has reported positive topline results from its Phase 2 SPRING trial of CM-101, a first-in-class monoclonal antibody, in patients with primary sclerosing cholangitis (PSC). The trial met its primary endpoint of safety and tolerability and demonstrated anti-fibrotic, anti-inflammatory, and anti-cholestatic effects across multiple secondary efficacy endpoints.

Key findings include:

• Statistically significant improvement in liver stiffness, a important PSC disease marker
• Reduction in total bilirubin, an important marker of cholestasis and liver health
• Improvements in pruritis, a cholestatic indicator relevant to patients
• Favorable safety profile and general tolerability over the 15-week treatment period

The company plans to advance CM-101 to a Phase 3 PSC trial in 2025, following discussions with the FDA later this year.

Chemomab Therapeutics announced new publications reinforcing the clinical potential of its CCL24-neutralizing antibody, CM-101, in treating primary sclerosing cholangitis (PSC). A study published in the International Journal of Molecular Science used machine learning to analyze proteomic profiles from PSC patient sera, confirming that high levels of CCL24 are linked to PSC severity and cirrhosis. This highlights the possibility of CM-101 as an effective therapy. A second study in Drug Safety reported that CM-101 showed good tolerability and reduced biomarkers of inflammation and fibrosis in Phase 1 trials. Topline data from the Phase 2 PSC trial is expected mid-2024.

Chemomab Therapeutics shared promising data at EASL 2024 and the Gordon Research Conference, showcasing the potential of CM-101 as a novel treatment for Primary Sclerosing Cholangitis (PSC). The studies highlighted CM-101's anti-fibrotic activity, evidenced by reduced liver fibroblast activation in ex vivo assays using patient samples. New translational data confirmed CM-101's disease-modifying effects in PSC. Proteomic profiling and machine learning developed a protein signature predicting PSC severity, reinforcing the therapeutic targeting of CCL24. These findings are pivotal as Chemomab approaches topline results from its Phase 2 PSC trial.

Chemomab Therapeutics (Nasdaq: CMMB), a clinical-stage biotech firm focusing on fibro-inflammatory diseases, has announced its participation in two significant scientific conferences. At the Gordon Research Conference on Chemotactic Cytokines (June 2-7, 2024, Portland, Maine), Prof. Amnon Peled will present on CCL24's role in liver fibrosis and inflammation. At the EASL Congress 2024 (June 5-8, 2024, Milan, Italy), Chemomab's team will present multiple posters on CM-101's anti-fibrotic activity and its potential for primary sclerosing cholangitis. Chemomab's corporate development team will also attend the BIO International Convention in San Diego (June 3-6, 2024) for partnering opportunities.

Chemomab Therapeutics announced its first quarter 2024 financial results and corporate update, highlighting early completion of patient enrollment in the CM-101 Phase 2 trial for primary sclerosing cholangitis, peer-reviewed publications validating the role of CCL24, and significant catalysts expected in late 2024/early 2025. The company also reported new patents granted in the E.U., Brazil, and Israel, and hosted an expert PSC webinar. Financially, Chemomab's cash position was $16.0 million as of March 31, 2024, with decreased R&D and G&A expenses.

Chemomab Therapeutics (Nasdaq: CMMB) has been granted a 180-day extension by Nasdaq to regain compliance with the minimum bid price rule. The company has until November 4, 2024, to ensure that the closing bid price of its American Depositary Shares (ADSs) is at least $1.00 per ADS for a minimum of 10 consecutive trading days. If the requirement is met, Nasdaq will confirm compliance, allowing Chemomab to maintain its listing on the Nasdaq Capital Market under the symbol 'CMMB'.

Chemomab Therapeutics (Nasdaq: CMMB) will have Dr. Adi Mor, the CEO, present at the Aegis Virtual Conference on May 7, 2024, discussing innovative therapeutics for fibro-inflammatory diseases. The presentation will be webcast live, offering further insights into the company's endeavors.